Advice
in the absence of a submission from the holder of the marketing authorisation
fentanyl citrate (Breakyl®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice77KB (PDF)
Medicine details
- Medicine name:
- fentanyl citrate (Breakyl)
- SMC ID:
- 947/13
- Indication:
- Treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.
- Pharmaceutical company
- Meda Pharmaceuticals Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 January 2014